首日上市破发!药明巨诺-B(2126.HK)半日收跌6.09%
格隆汇11月3日丨CAR-T重磅玩家药明巨诺-B(2126.HK)今日首日上市早盘一度冲高涨8.19%报25.75港元,随后跳水走低,截至半日收盘跌6.09%报22.35港元,成交9.06亿港元,换手率17.19%,最新总市值49亿港元。该股此次IPO价格为23.8港元,净筹21.967亿港元。药明巨诺是中国领先的细胞治疗公司,主打候选产品relma-cel是一款针对复发或难治B细胞淋巴瘤的自体抗CD19 CAR-T产品。药明巨诺在招股书中表示,倘若能按目前预计的时间获批在中国上市,预计relma-cel将成为中国首个获批一类生物制品CAR-T疗法。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.